Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

Pharmacy World and Science

Volumn 28, Issue 4, 2006, Pages 207-214

  Sancar, Mesut ^a   Izzettin, Fikret Vehbi ^a   Apikoglu Rabus, Sule ^a   Besisik, Fatih ^b   Tozun, Nurdan ^a   Dulger, Gul ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cost effectiveness; Eradication regimens; Gastritis; Helicobacter pylori; Peptic ulcer; Pharmacoeconomics

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CALCULATION; CHRONIC GASTRITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; ENDOSCOPY; FEMALE; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AMOXICILLIN; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MELENA; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; RANITIDINE; TASTE DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750560003     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9021-y     Document Type: Article

References (36)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
2. Veldhuyzen SO, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Can Med Assoc J 1997;156:1565-72.
3. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996;91:246-57.
4. Van Der Weyden MB, Armstrong RM, Gregory AT. The 2005 Nobel Prize in physiology or medicine. The Helicobacter story illustrates some of the human hallmarks of revolutionary research. Med J Aust 2005;183:612-4.
5. McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996;110:926-38.
6. Go MF. What are the host factors that place an individual at risk for Helicobacter pylori associated disease? Gastroenterology 1997;113(Suppl.):S15- S20.
7. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori. MALT lymphoma study group. Lancet 1995;345:1591-4.
8. Fendrick AM. Outcomes research in Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11(Suppl. 1):95-101.
9. Fendrick AM. The role of economic evaluation in the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Clin N Am 2000;29:837-51.
10. Marshall BJ. Helicobacter pylori: the etiologic agent for peptic ulcer. JAMA 1995;274:1064-6.
11. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995;9(Suppl. 2):59-69.
12. Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, McColl KE, Myres P, Delaney BC. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838-44.
13. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.
14. Tennvall GR, Norinder A, Ohlin B. Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. Pharmacoeconomics 1999;16:297-306.
15. Chen SY, Wang JY, Chen J, Zhang XD, Zhang SS. Assessment of decisions in the treatment of Helicobacter pylori related duodenal ulcer: a cost-effectiveness study. J Gastroenterol Hepatol 1999;14:977-83.
16. Vakil N. Are the geographical and regional differences in Helicobacter pylori eradication? Can J Gastroenterol 2003;17(Suppl. B):30B-32B.
17. McLoughin RM, O'Morain CA, O'Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005;19:421-7.
18. O'Brien B, Goeree R, Mohammed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995;155:1958-64.
19. Duggan AE, Tolley K, Hawkey CJ, Logan RFA. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. BMJ 1998;316:1648-54.
20. Marko D, Calvet X, Ducons J, Gnardiola J, Tito L, Bory F. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter 2005;10:22-32.
21. Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87-97.
22. Andersen LP, Colding H, Kristiansen JE. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. Int J Antimicrob Agents 2000;14:231-4.
23. Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 2000;14:885-9.
24. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. NEJM 1995;333:984-91.
25. Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, et al. One week ranitidine bismuth citrate versus colloidal bismuth subcitrate based anti-helicobacter triple therapy. Am J Gastroenterol 1999;94:721-4.
26. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
27. Kantarceken B, Yildirim B, Karincaoglu M, Aladag M, Hilmioglu F. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000;11:25-9.
28. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323-9.
29. Vcev A, Stimac D, Vceva A, Takac B, Pezerovic D, Ivandic A. High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. Helicobacter 1999;4:54-7.
30. Calvet X, Gene E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for Helicobacter pylori? Aliment Pharmacol Ther 2001;15:1067-76.
31. Jönsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand J Gastroenterol 1996;31(Suppl. 215):90-5.
32. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005;10:40-46.
33. Clifton S, Galt K. Treatment of Helicobacter pylori infection. Immanuel Medical Center Pharmacy Memo 1997.
34. Eralp Y, Davutoglu C, Uzunismail H, Oktay E. Efficacy of combination therapy with omeprazole, amoxicillin and clarithromycin treatment of patients with Helicobacter pylori associated gastritis and duodenal ulcer disease. Turk J Gastroenterol 1999;10:27-31.
35. Unge P. Review of H. pylori eradication regimens. Scand J Gastroenterol 1996;31(Suppl. 2):74-81.
36. Cutler AF, Vakil N. Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease. Am J Man Care 1997;3:1528-34.